Assenagon Asset Management S.A. Chinook Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 18, 2023	BUY	$21.53 - $26.8 $10.4 Million - $13 Million	483,220 Added 54.4%	1,371,469 $31.7 Million
Q4 2022 Jan 12, 2023	SELL	$18.63 - $27.35 $10.1 Million - $14.9 Million	-543,145 Reduced 37.95%	888,249 $23.3 Million
Q3 2022 Oct 27, 2022	BUY	$17.51 - $23.37 $6.47 Million - $8.64 Million	369,512 Added 34.8%	1,431,394 $28.1 Million
Q2 2022 Jul 27, 2022	BUY	$12.59 - $18.8 $13.4 Million - $20 Million	1,061,882 New	1,061,882 $18.6 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.